Chronic recurrent multifocal osteomyelitis (CRMO) was first described in 1972 by Giedion et al. (1). It is a rare disease with an unknown aetiology, which accounts for 2-5% of all bone inflammations (2). Although it usually affects children aged 4-14 years and young adults, cases of adult patients have also been reported in the literature. There is a significant predominance of female patients (5:1), while the incidence of CRMO is similar for all races (3, 4). CRMO is characterised by recurrent episodes of osteitis without a specific infectious agent. The disease lasts from several months up to several years with periods of exacerbations and remissions, as well as a self-limiting tendency of the inflammatory process (3). Although lesions may occur in any location, such as vertebrae, pelvic bones, metacarpus, metatarsus, sternum and clavicles, in most clinical cases they are found in the metaphysis of long bones, femoral and tibial bones in particular (5, 6). They are rarely found in the mandible, where they occur in the form of a single, isolated focal lesion (7, 8). Although the aetiology of the disease is not fully understood, the available literature devotes a lot of attention to genetic, autoimmune and bacterial factors (3). The clinical manifestations of CRMO include gradually increasing bone pain, local tenderness, soft tissue oedema, skin reddening and mild fever. Severe pain may limit patient’s activity and is a frequent reason for hospital stay (4). Although CRMO usually occurs as a single disease, there are cases of chronic recurrent multifocal osteomyelitis coexisting with inflammatory diseases showing signs of autoimmunisation, e.g. ulcerative colitis or Crohn’s disease (9-11). According to the latest literature data, it is believed that CRMO is a paediatric variant of SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) in adults, which produces symptoms such as synovitis, acne, pustular psoriasis of the hands and feet, bone hypertrophy and inflammation (3). Due to the unclear clinical picture and the course of disease, the diagnosis of CRMO is difficult and requires differentiation with bone neoplasias, infectious and autoimmune diseases (3). The diagnostic process involves a series of laboratory (serology, microbiology) and imaging (radiology, including the whole body skeletal scintigraphy, CT and MRI) investigations. Tissue biopsy is necessary to exclude infectious and neoplastic processes (12-14). CRMO is treated empirically. Despite an aseptic course of the disease, long-term antibiotic therapy is usually used, which does not bring the expected result, but supports the treatment (15). Non-steroidal anti-inflammatory drugs are recommended as first-line agents. If no improvement is observed, systemic glucocorticosteroids are included. Currently, high hopes are pinned on bisphosphonate therapy, particularly in cases of multifocal lesions. Intravenous, cyclic infusions of pamidronic acid are used in children. It was found that the compound causes rapid and significant pain alleviation, reduces serum inflammatory markers, as well as induces regression of inflammatory lesions in the bones, as confirmed in MRI (16).